Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | BAD | Q92934 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2254810 | 1.00 | BCL2L1 (0.47) | BCL2L1BADMTNR1AMTNR1BDHODH | |
| SCHEMBL2253758 | 0.94 | MTNR1A (0.48) | BCL2L1BADMTNR1AMTNR1BNQO2 | |
| SCHEMBL2253763 | 0.94 | MTNR1A (0.48) | BCL2L1BADMTNR1AMTNR1BNQO2 | |
| SCHEMBL2253096 | 0.88 | BCL2L1 (0.49) | BCL2L1BADDHODHFDPS | |
| SCHEMBL2253099 | 0.88 | BCL2L1 (0.49) | BCL2L1BADDHODHFDPS | |
| SCHEMBL2254705 | 0.82 | BCL2L1 (0.49) | BCL2L1BADMTNR1AMTNR1BDHODH | |
| SCHEMBL2254708 | 0.82 | BCL2L1 (0.49) | BCL2L1BADMTNR1AMTNR1BDHODH | |
| SCHEMBL2253025 | 0.79 | BCL2L1 (0.56) | BCL2L1BADMTNR1AMTNR1BDHODH | |
| SCHEMBL2253023 | 0.79 | BCL2L1 (0.56) | BCL2L1BADMTNR1AMTNR1BDHODH | |
| SCHEMBL2255846 | 0.76 | MTNR1A (0.56) | MTNR1AMTNR1BNQO2HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904047-B1 | APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2013-01-02 | — | — | EP | disclosed |
| US-7989656-B2 | Biaryl carboxylic acid apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100234456-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2010-09-16 | — | — | US | disclosed |
| US-7750004-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-06 | — | — | US | disclosed |
| US-20070135392-A1 | Apoptosis promoters | ABBVIE INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234456-A1 | APOPTOSIS PROMOTERS | MCL1, BAX, BCL2 | BCL2L1 5/4885BAD 11/4885MTNR1A 1544/4885 |
| US-20070135392-A1 | Apoptosis promoters | MCL1, BAX, BCL2 | BCL2L1 5/4885BAD 11/4885MTNR1A 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.